China NMPA Drug Inspection - Hangzhou Huadong Medicine Group Xinwufeng Pharmaceutical Co., Ltd. - Oryzanol tablets
China NMPA drug inspection for Hangzhou Huadong Medicine Group Xinwufeng Pharmaceutical Co., Ltd. published January 18, 2018. Drug: Oryzanol tablets. The Ningxia Food and Drug Administration issued an announcement on January 18, 2018, detailing the outcomes of a regiona
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hangzhou Huadong Medicine Group Xinwufeng Pharmaceutical Co., Ltd. published January 18, 2018. Drug: Oryzanol tablets. The Ningxia Food and Drug Administration issued an announcement on January 18, 2018, detailing the outcomes of a regiona
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox